Labroots

Mitigating ADC Toxicities With Linker-Payload Design

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
News-Medical.Net

Unveiling ADC cellular internalization with pH-sensitive dye detection

Learn how pH-sensitive dye detection supports reliable ADC internalization assays and insight into cellular uptake mechanisms ...
GEN

Accelerating ADC Discovery and Development with Novel Payload-Linker and Conjugation Technologies

Antibody-Drug Conjugates (ADCs) are a fast-growing modality in both cancerous and non-cancerous indications. To date 15 ADCs have been approved by the regulatory agencies as therapies for various ...
La Grande Observer

Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025

SAN DIEGO, March 25, 2025 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other ...
Fierce Biotech

Roche returns to MediLink with promise of $570M near-term payments for another ADC

In return for the rights to YL201 outside China, MediLink will receive upfront and potential near-term milestone payments that could reach a combined $570 million. The Thursday evening release also ...
WGHP

Baylink Biosciences to Present Its Novel Linker and Payload Technologies at 3rd ADC Linker & Conjugation Summit

PALO ALTO, CA, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today ...
Nasdaq

Akari Advances Towards First-in-Human Trial With Novel ADC Payload

(RTTNews) - Akari Therapeutics, Plc (Nasdaq: AKTX) yesterday announced that it has initiated GMP manufacturing of its lead antibody-drug conjugate (ADC), AKTX-101, marking a pivotal step toward its ...

NextCure Provides Business Update

Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose ...
GEN

Bioconjugates Meet and Promise to Exceed Expectations

One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform -- Sidewinder's pipeline of precision bispecific ADCs combined with Lonza's clinically validated ...
Business Wire

Antibody Drug Conjugate Market Industry Report 2024-2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key Geographical Regions ...

DUBLIN--(BUSINESS WIRE)--The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key ...